BGB-A445, a novel non-ligand-blocking agonistic anti-OX40 antibody, exhibits superior immune activation and antitumor effects in preclinical models
{{custom_author.name}}, {{article.zuoZheEn}}
BGB-A445, a novel non-ligand-blocking agonistic anti-OX40 antibody, exhibits superior immune activation and antitumor effects in preclinical models
[{{custom_ref.label}}] |
{{custom_citation.content}}
|
/
〈 | 〉 |